Nektar Therapeutics (NKTR) Net income 2016–2025
Nektar Therapeutics (NKTR) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
-$164.1MFY2025 · since FY2016: -$153.5M → -$164.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$164.1M | -37.9% |
| FY2024 | -$119.0M | +56.9% |
| FY2023 | -$276.1M | +25.0% |
| FY2022 | -$368.2M | +29.7% |
| FY2021 | -$523.8M | -17.9% |
| FY2020 | -$444.4M | -0.9% |
| FY2019 | -$440.7M | -164.7% |
| FY2018 | $681.3M | +804.6% |
| FY2017 | -$96.7M | +37.0% |
| FY2016 | -$153.5M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More NKTR financial trends
NKTR RevenueNKTR Net marginNKTR Gross profitNKTR Gross marginNKTR Operating incomeNKTR Operating marginNKTR Operating cash flowNKTR Free cash flowNKTR Capital expendituresNKTR Return on equityNKTR Stock buybacksNKTR Dividends paidNKTR Total assetsNKTR Total liabilitiesNKTR Shareholders’ equityNKTR overview →